Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Lewis Base Catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Advanced synthesis of astemizole key intermediates using fluorescent organoboron catalysts. Delivers high purity, metal-free processes, and scalable supply chain solutions.
Patent CN102391060B details a green acetylation method using [HDBU]OAc. High yields, solvent-free conditions offer significant supply chain advantages for pharma intermediates.
Novel Lewis base catalyzed route offers high purity pharmaceutical intermediates with streamlined supply chain and cost efficiency for global buyers.
Patent CN110343053B details a high-yield, solvent-free synthesis route for N-(2-ethoxyphenyl)-N'-(4-ethylphenyl)-oxalamide, offering significant cost and purity advantages for industrial supply chains.
Patent CN102432487A reveals a green aminoacetylation method using [HDBU]OAc. This technology offers high purity, solvent-free conditions, and significant cost reduction for API manufacturing.
Patent CN105439967A reveals metal-free triazole synthesis. Offers cost reduction and supply reliability for pharmaceutical intermediate manufacturing.
Patent CN121021345A reveals a mild Lewis base catalyzed route for sulfenamides. This method offers significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN103360410B details a novel trimethylchlorosilane protection route enhancing yield and purity for scalable Ofloxacin USP 23 manufacturing supply chains.
Patent CN105622537A details a Lewis base-catalyzed route for isoxazoles, offering cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN105622537A reveals a metal-free synthesis for 3,4,5-trisubstituted isoxazoles. Discover cost-effective, scalable pharmaceutical intermediate manufacturing solutions.
Patent CN106674178A reveals a metal-free DBU-catalyzed route for chromans, offering high yields and reduced environmental impact for reliable pharmaceutical intermediate suppliers.
Patent CN105622537A enables eco-friendly production of high-purity isoxazole intermediates through Lewis base catalysis with mild conditions and consistent yields above 90%, ensuring cost reduction and reliable supply for pharmaceutical manufacturing.